1. Scrip
  2. >>Business
  3. >>Deals

Biogen's Return Of Rights To InnoCare Deals Blow To Made In China Innovation

Stress Test And Cash Crunch Continues

 
• By Brian Yang

Biogen’s return of rights to the BTK inhibitor orelabrutinib to originator InnoCare signals an ongoing tough reality for Chinese biotechs with go-global ambitions.

Stressed
Biogen's return of rights shows tough road remains ahead for Chinese biotech innovation • Source: Shutterstock

A continuing downturn for the Chinese biotech sector in 2022 appears to be flowing through into 2023, when the going is so far remaining tough.

Beijing-based InnoCare Pharma Ltd. disclosed on 16 February that the global licensing partner for its lead asset, Biogen, Inc

More from Deals

More from Business